Literature DB >> 25511698

The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways.

Solange Tréhoux1, Bélinda Duchêne1, Nicolas Jonckheere1, Isabelle Van Seuningen2.   

Abstract

MUC1 is an oncogenic mucin overexpressed in several epithelial cancers, including pancreatic ductal adenocarcinoma, and is considered as a potent target for cancer therapy. To this aim, we undertook to study MUC1 biological effects on pancreatic cancer cells and identify pathways mediating these effects. Our in vitro experiments indicate that inhibiting MUC1 expression decreases cell proliferation, cell migration and invasion, cell survival and increases cell apoptosis. Moreover, lack of MUC1 in these cells profoundly altered their sensitivity to gemcitabine and 5-Fluorouracil chemotherapeutic drugs. In vivo MUC1-KD cell xenografts in SCID mice grew slower. Altogether, we show that MUC1 oncogenic mucin alters proliferation, migration, and invasion properties of pancreatic cancer cells and that these effects are mediated by p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemoresistance; Invasion; MUC1; Migration; Pancreatic cancer; Proliferation

Mesh:

Substances:

Year:  2014        PMID: 25511698     DOI: 10.1016/j.bbrc.2014.12.025

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  26 in total

1.  MUC5AC interactions with integrin β4 enhances the migration of lung cancer cells through FAK signaling.

Authors:  I Lakshmanan; S Rachagani; R Hauke; S R Krishn; S Paknikar; P Seshacharyulu; S Karmakar; R K Nimmakayala; G Kaushik; S L Johansson; G B Carey; M P Ponnusamy; S Kaur; S K Batra; A K Ganti
Journal:  Oncogene       Date:  2016-01-11       Impact factor: 9.867

Review 2.  Physicochemical properties of mucus and their impact on transmucosal drug delivery.

Authors:  Jasmim Leal; Hugh D C Smyth; Debadyuti Ghosh
Journal:  Int J Pharm       Date:  2017-09-14       Impact factor: 5.875

3.  Molecular Pathways: Mucins and Drug Delivery in Cancer.

Authors:  Chinthalapally V Rao; Naveena B Janakiram; Altaf Mohammed
Journal:  Clin Cancer Res       Date:  2016-12-30       Impact factor: 12.531

4.  Chemoresistance in pancreatic cancer: Emerging concepts.

Authors:  Manu Gnanamony; Christopher S Gondi
Journal:  Oncol Lett       Date:  2017-02-24       Impact factor: 2.967

5.  Bromelain and acetylcysteine (BromAc®) alone and in combination with gemcitabine inhibit subcutaneous deposits of pancreatic cancer after intraperitoneal injection.

Authors:  Ahmad H Mekkawy; Krishna Pillai; Hyerim Suh; Samina Badar; Javed Akhter; Vahan Képénékian; Kevin Ke; Sarah J Valle; David L Morris
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

6.  Polyplex-mediated inhibition of chemokine receptor CXCR4 and chromatin-remodeling enzyme NCOA3 impedes pancreatic cancer progression and metastasis.

Authors:  Yan Wang; Sushil Kumar; Satyanarayana Rachagani; Balasrinivasa R Sajja; Ying Xie; Yu Hang; Maneesh Jain; Jing Li; Michael D Boska; Surinder K Batra; David Oupický
Journal:  Biomaterials       Date:  2016-05-27       Impact factor: 12.479

7.  Muc1 promotes migration and lung metastasis of melanoma cells.

Authors:  Xiaoli Wang; Hongwen Lan; Jun Li; Yushu Su; Lijun Xu
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

8.  Mucins in pancreatic cancer: biological role, implications in carcinogenesis and applications in diagnosis and therapy.

Authors:  Hyerim Suh; Krishna Pillai; David Lawson Morris
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

9.  Mucin 1 promotes radioresistance in hepatocellular carcinoma cells through activation of JAK2/STAT3 signaling.

Authors:  Feng-Tao Yi; Qi-Ping Lu
Journal:  Oncol Lett       Date:  2017-10-03       Impact factor: 2.967

Review 10.  Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer?

Authors:  John Kokkinos; Anya Jensen; George Sharbeen; Joshua A McCarroll; David Goldstein; Koroush S Haghighi; Phoebe A Phillips
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.